| Literature DB >> 29298876 |
Mingfeng Zheng1, Shiyuan Shi1, Wei Wei1, Qi Zheng1, Yifan Wang1, Xiaozhang Ying1, Di Lu2.
Abstract
OBJECTIVE: The present study investigated the clinical significance of mannose-binding lectin 2 (MBL2), cluster of differentiation 14 (CD14) and tumour necrosis factor-α (TNF-α) gene polymorphisms in patients with spinal tuberculosis (TB) in Chinese population.Entities:
Keywords: Cluster of differentiation 14; Mannose-binding lectin; Single nucleotide polymorphism; Spinal tuberculosis; Tumor necrosis factor- α
Mesh:
Substances:
Year: 2018 PMID: 29298876 PMCID: PMC5794501 DOI: 10.1042/BSR20171140
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
The primer sequences for MBL2, CD14 and TNF-α gene amplification
| Gene/polymorphism | Primer | |
|---|---|---|
| TNF-238/244 | Forward | 5′-CCTCAAGGACTCAGCTTTCGT-3′ |
| Reverse | 5′-ACACTCCCCATCCTCCCACATC-3′ | |
| TNF-863 | Forward | 5′-GGCTCTGAGGAATGGGTTAC-3′ |
| Reverse | 5′-CCTCTACATGGCCCTGTCTAC-3′ | |
| TNF-857 | Forward | 5′-GGCTCTGAGGAATGGGTTAC-3′ |
| Reverse | 5′-CCTCTACATGGCCCTGTCTAC-3′ | |
| TNF-308 | Forward | 5′-AGGCAATAGGTTTTGAGGGCCAT-3′ |
| Reverse | 5′-TCCTCCCTGCTCCGATTCCG-3′ | |
| MBL2 | Forward | 5′-GCCAGTGGTTTTTGACTCAC-3′ |
| Reverse | 5′-GGAGTATAGGGGTCCGTCA-3′ | |
| CD14 −159C>T | Forward | 5′-GCCAACAGATGAGGTTCACA-3′ |
| Reverse | 5′-GTTCGACCCCAAGACCCTAC-3′ |
The genotypic and allelic frequencies of MBL2 gene polymorphisms between spinal tuberculosis and controls
| Patients ( | Control ( | Adjusted | Adjusted OR | 95% CI | |
|---|---|---|---|---|---|
| Genotype | |||||
| HH | 14 (5.83%) | 20 (13.33%) | Ref | 1.00 | Ref |
| HL | 120 (50.00%) | 61 (40.67%) | 0.152 | 1.98 | 0.74–5.14 |
| LL | 106 (44.17%) | 69 (46.00%) | 0.071 | 2.31 | 0.91–5.87 |
| HL + LL | 226 (94.17%) | 130 (86.67%) | 0.081 | 2.16 | 0.87–5.29 |
| Allele | |||||
| H | 130 (27.08%) | 98 (32.67%) | Ref | 1.00 | Ref |
| L | 350 (72.92%) | 202 (67.33%) | 0.074 | 1.40 | 0.97–2.01 |
| Genotype | |||||
| YY | 149 (62.08%) | 112 (74.67%) | Ref | 1.00 | Ref |
| XY | 84 (35.00%) | 33 (22.00%) | 0.021 | 1.87 | 1.13–4.15 |
| XX | 7 (2.92%) | 7 (4.67%) | 1 | 0.97 | 0.20–4.18 |
| YX + XX | 67 (27.92%) | 39 (26.00%) | 0.062 | 1.71 | 0.95–3.01 |
| Allele | |||||
| Y | 409 (85.21%) | 256 (85.33%) | Ref | 1.00 | Ref |
| X | 71 (14.79%) | 14 (14.67%) | 0.109 | 1.47 | 0.87–2.27 |
| Genotype | |||||
| PP | 144 (60.00%) | 110 (73.33%) | Ref | 1.00 | Ref |
| PQ | 82 (34.17%) | 34 (22.67%) | 0.014 | 1.91 | 1.12–6.31 |
| 14 (5.83%) | 6 (4.00%) | 0.365 | 1.79 | 0.51–3.54 | |
| PQ + QQ | 96 (40.00%) | 40 (26.67%) | 0.022 | 1.85 | 1.07–3.24 |
| Allele | |||||
| P | 330 (7.08%) | 253 (84.33%) | Ref | 1.00 | Ref |
| Q | 110 (22.92%) | 47 (15.67%) | 0.012 | 2.65 | 1.09–4.51 |
Figure 1The sequence map of MBL2 gene polymorphisms
(A) The −550C>G polymorphism in the MBL2 gene. (B) The −221G>C polymorphism in the MBL2 gene. (C) The +4C>T polymorphism in the MBL2 gene. (D) The −159C>T polymorphism in the CD14 gene. (E) The 238 G>A polymorphism in the TNF-α gene. (F) The 224G>A polymorphism in the TNF-α gene. (G) The 863C>A polymorphism in the TNF-α gene. (H) The 857C>T polymorphism in the TNF-α gene. (I) The 308G>A polymorphism in the TNF-α gene.
The genotypic and allelic frequencies of CD14 gene polymorphisms between spinal tuberculosis and controls
| Patients ( | Control ( | Adjusted | Adjusted OR | 95% CI | |
|---|---|---|---|---|---|
| Genotype | |||||
| CC | 36 (15.00%) | 44 (18.33%) | Ref | 1.00 | Ref |
| CT | 132 (55.00%) | 81 (33.75%) | 0.512 | 1.05 | 0.65–1.64 |
| TT | 72 (30.00%) | 25 (10.42%) | 0.021 | 1.68 | 1.02–3.58 |
| CT + TT | 204 (85.00%) | 106 (44.17%) | 0.032 | 2.10 | 1.09–3.85 |
| Allele | |||||
| C | 204 (42.50%) | 84 (56.00%) | Ref | 1.00 | Ref |
| T | 276 (57.50%) | 66 (44.00%) | 0.001 | 1.97 | 1.24–3.42 |
The genotypic and allelic frequencies of TNF-α gene polymorphisms between spinal tuberculosis and controls
| Patients ( | Control ( | Adjusted | Adjusted OR | 95% CI | |
|---|---|---|---|---|---|
| Genotype | |||||
| GG | 217 (90.42%) | 143 (95.33%) | Ref | 1.00 | Ref |
| GA | 23 (9.58%) | 7 (4.67%) | 0.525 | 1.14 | 0.79–1.54 |
| AA | 0 (0) | 0 (0) | NA | NA | NA |
| GA + AA | 23 (9.58%) | 7 (4.67%) | 0.154 | 1.62 | 0.95–1.67 |
| Allele | |||||
| G | 457 (95.21%) | 293 (97.67%) | Ref | 1.00 | Ref |
| A | 23 (4.79%) | 7 (2.33%) | 0.512 | 1.75 | 0.80–1.58 |
| Genotype | |||||
| GG | 240 (100%) | 150 (100%) | NA | NA | NA |
| GA | 0 (0) | 0 (0) | NA | NA | NA |
| AA | 0 (0) | 0 (0) | NA | NA | NA |
| GA + AA | 0 (0) | 0 (0) | NA | NA | NA |
| Allele | |||||
| G | 480 (100%) | 300 (100%) | NA | NA | NA |
| A | 0 (0) | 0 (0) | NA | NA | NA |
| Genotype | |||||
| CC | 178 (74.17%) | 108 (72.00%) | Ref | 1.00 | Ref |
| CA | 54 (22.50%) | 42 (28.00%) | 0.254 | 1.21 | 0.77–1.04 |
| AA | 8 (3.33%) | 0 (0) | 0.375 | 1.14 | 0.75–1.01 |
| CA + AA | 62 (25.83%) | 42 (28.00%) | 0.275 | 1.17 | 0.78–1.24 |
| Allele | |||||
| C | 410 (85.42%) | 258 (86.00%) | Ref | 1.00 | Ref |
| A | 70 (14.58%) | 42 (14.00%) | 0.385 | 1.05 | 0.81–0.94 |
| Genotype | |||||
| CC | 132 (55.00%) | 172 (84.67%) | Ref | 1.00 | Ref |
| CT | 108 (45.00%) | 26 (17.33%) | <0.001 | 8.85 | 2.42–30.84 |
| TT | 0 (0) | 3 (2.00%) | 0.245 | 2.35 | 0.21–3.54 |
| CT + TT | 108 (45.00%) | 29 (19.33%) | <0.001 | 9.87 | 2.55–34.85 |
| Allele | |||||
| C | 372 (77.50%) | 268 (89.33%) | Ref | 1.00 | Ref |
| T | 108 (22.50%) | 32 (10.67%) | 0.001 | 7.54 | 2.54–25.87 |
| Genotype | |||||
| GG | 21790.42%) | 127 (84.67%) | Ref | 1.00 | Ref |
| GA | 23 (9.58%) | 23 (15.33%) | 0.412 | 1.07 | 0.86–1.05 |
| AA | 0 (0) | 0 (0) | NA | NA | NA |
| GA + AA | 23 (9.58%) | 23 (15.33%) | 0.211 | 1.54 | 0.95–1.38 |
| Allele | |||||
| G | 457 (95.21%) | 277 (92.33%) | Ref | 1.00 | Ref |
| A | 23 (4.79%) | 23 (7.67%) | 0.387 | 1.41 | 0.87–1.27 |